Evidence For Pd 1 Pd L1 Combination Immunotherapie

Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Gulley, James L; Madan, Ravi A; Arlen, Philip M

What’s new in melanoma? Combination!

P. Ascierto, F. Marincola, M. Atkins

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

Hu-Lieskovan, Siwen, Robert, Lidia, Homet Moreno, Blanca, Ribas, Antoni

T-cell exhaustion in the tumor microenvironment

Jiang, Yuyong, Li, Yongsheng, Zhu, Bo

Targeting regulatory T cells in tumor immunotherapy

Smyth, Mark J., Ngiow, Shin Foong, Teng, Michele W.L.

Of Mice and Not Men: Differences between Mouse and Human Immunology

Mestas, Javier, Hughes, Christopher C.W.

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, Caroline, Schachter, Jacob, Long, Georgina V., Arance, Ana, Grob, Jean‐J

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTL

Peggs, Karl S., Quezada, Sergio A., Chambers, Cynthia A., Korman, Alan J., Allis

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.

Voron, Thibault; Colussi, Orianne; Marcheteau, Elie et al.

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Sakuishi, Kaori, Apétoh, Lionel, Sullivan, Jenna M., Blazar, Bruce R., Kuchroo,

Mechanisms of targeting cd28 by a signaling monoclonal antibody in acute and chronic allograft rejection1

Dong, Victor, Yuan, Xueli, Coito, Ana J., Waaga, Ana Maria, Sayegh, Mohamed H.,

Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antig

Agarwala, Sanjiv S.

Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity

Ramsay, Alan G.

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4

Dewan, Md. Zahidunnabi; Galloway, Ashley E.; Kawashima, Noriko et al.

Mechanism and Therapeutic Reversal of Immune Suppression in Cancer

Herber, Donna L., Nagaraj, Srinivas, Djeu, Julie Y., Gabrilovich, Dmitry I.

PD-L1 Expression in Triple-Negative Breast Cancer

Mittendorf, Elizabeth A., Philips, Anne V., Meric‐Bernstam, Funda, Qiao, Na, Wu,

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity,

Brahmer, Julie R., Drake, Charles G., Wollner, Ira, Powderly, John D., Picus, Jo

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

Linch, Stefanie N; McNamara, Michael J; Redmond, William L

Regulatory T cell: a protection for tumour cells

Yi Wang, Yushui Ma, Ying Fang, Shengdi Wu, Lili Liu, D. Fu, Xizhong Shen

Molecular basis of T cell inactivation by CTLA-4.

Kyung-Mi Lee, Ellen Chuang, M. Griffin, R. Khattri, David Hong, Weiguo Zhang, D.

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

Dhodapkar, Madhav V., Sznol, Mario, Zhao, Biwei, Wang, Ding, Carvajal, Richard D

Current and Emerging Perspectives on Immunotherapy for Melanoma.

Daud, Adil

Combined Immune Checkpoint Blockade.

Drake, Charles G

Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions.

Atkins, Michael

A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in hig

N. Wages, C. Slingluff, G. Petroni

Radiotherapy complements immune checkpoint blockade.

Ngiow, Shin Foong; McArthur, Grant A; Smyth, Mark J

Nivolumab plus ipilimumab in the treatment of advanced melanoma.

Tsai, Katy K, Daud, Adil I

Combination immunotherapy: Where do we go from here?

Overacre-Delgoffe, Abigail E., Kurtuluş, Sema, Sznol, Mario, Pardoll, Drew M., A

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and C

Kohlhapp, Frederick J, Broucek, Joseph R, Hughes, Tasha, Huelsmann, Erica J, Lus

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

Feng, Zipei, Puri, Sachin, Moudgil, Tarsem, Wood, William J., Hoyt, Clifford, Wa

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete contr

Lussier, Danielle M, Johnson, John L, Hingorani, Pooja, Blattman, Joseph N

Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy

M. Castro, N. Goldstein

A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremeli

Callahan, Margaret K., Ott, Patrick A., Odunsi, Kunle, Bertolini, Stephane V., P

A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer

Fong, Lawrence, Kavanagh, Brian D., Rini, Brian I., Shaw, Vanessa, Weinberg, Viv

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV mela

A. Tarhini, J. Cherian, S. Moschos, H. Tawbi, Yongli Shuai, W. Gooding, C. Sande

Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansio

Fong, Lawrence, Kavanagh, Brian D., Hou, Yayi, O’Brien, Shaun, Carrasco‐Valiente

Emerging immunotherapies in ovarian cancer.

Ojalvo, Laureen S, Nichols, Paige E, Jelovac, Danijela, Emens, Leisha A

Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma.

Doyle, Chase

Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvan

Davila, Eduardo, Kennedy, Richard, Celis, Esteban

Immune targeting in breast cancer.

Cimino‐Mathews, Ashley, Foote, Jeremy B., Emens, Leisha A.

Propelling Immunotherapy Combinations Into the Clinic.

Tchekmedyian, Nishan, Gray, Jhanelle E, Creelan, Benjamin C, Chiappori, Alberto

Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Nguyen, T, Urban, J, Kalinski, P

Single versus combination immunotherapy drug treatment in melanoma

Grimaldi, Antonio Maria, Marincola, Francesco M., Ascierto, Paolo A.

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Wang, Xiang-Yang; Zuo, Daming; Sarkar, Devanand et al.

Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.

Youlin, Kuang; Li, Zhang; Xiaodong, Weng et al.

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

Junttila, Teemu T., Li, Ji, Johnston, Jennifer, Hristopoulos, Maria, Clark, Roby

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and

Fong, Lawrence, Kwek, Serena S, O'Brien, Shaun, Kavanagh, Brian, McNeel, Douglas

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anat

Kluger, Harriet M, Zito, Christopher R, Barr, Meaghan L, Baine, Marina K, Chiang

Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mo

Morales‐Kastresana, Aizea, Sanmamed, Miguel F., Rodríguez, Inmaculada, Palazón,

Combination Immunotherapy for Melanoma.

Kaufman, Howard L

Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy

Lee, Lucy, Gupta, Manish, Sahasranaman, Srikumar

Precision and predictive medicine in urothelial cancer: are we making progress?

Bellmunt, Joaquim, Orsola, Anna, Sonpavde, Guru

Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Kaliński, Paweł, NGUYEN, TRANG, Urban, Julie

Integrating Costimulatory Agonists to Optimize Immune-Based Cancer Therapies

Pardee, Angela D., Wesa, Amy, Storkus, Walter J.

T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy.

Melero, Ignacio, Rouzaut, Ana, Motz, Greg T, Coukos, George

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of

Redmond, William L, Linch, Stefanie N, Kasiewicz, Melissa J

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling

Chae, Young Kwang, Chung, Su Yun, Davis, Andrew A., Carneiro, Benedito A., Chand

Immunotherapy in upper GI malignancies.

Murphy, Adrian, Kelly, Ronan J

Combination of agonist anti-OX40 therapy with CTLA-4 blockade augments anti-tumor effector CD4 and CD8 T cells (P4318)

William L. Redmond, Stefanie N. Linch, Melissa J. Kasiewicz

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocy

Kim, Peter S; Jochems, Caroline; Grenga, Italia et al.

Comparative combination cancer immunotherapy with vaccination, checkpoint inhibition and TNFRSF stimulation (VAC12P.1021

Taylor H. Schreiber, E. Podack

Use of HSP90 inhibitors in the combination immunotherapy of melanoma (P4272)

Subhara Raveendran, A. Rao, W. Storkus

Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma

S. Pilon-Thomas, A. Mackay, N. Vohra, J. Mulé

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies.

Verbrugge, Inge, Galli, Mara, Smyth, Mark J, Johnstone, Ricky W, Haynes, Nicole

Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma.

Zibelman, Matthew; Olszanski, Anthony

Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics.

Wang, Daniel Y, Sosman, Jeffrey A, Johnson, Douglas B

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Hurwitz, Arthur A., Foster, Barbara A., Kwon, Eugene D., Truong, Tan, Choi, Euge

Immunotherapy: combine and conquer

VOICES: Clinical Trials Remain Essential to Evaluate Combination Immunotherapies, and Against a Broader Range of Cancers

J. Wolchok

Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Mahvi, David A, Meyers, Justin V, Tatar, Andrew J, Contreras, Amanda, Suresh, Ma

Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.

Martinez Forero, Ivan, Okada, Hideho, Topalian, Suzanne L, Gajewski, Thomas F, K

Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tu

B. Minev, H. Kohrt, M. Kilinc, N. Chen, A. Feng, M. Pessian, Ulrike Geissinger,

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human

Dhodapkar, Kavita M., Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, G

Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR

Gordon Moody, J. Moriguchi, Ji-rong Sun, P. McElroy, H. Tan, Yannick Bulliard, B

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph node

Broucek, Joseph, Hughes, Tasha M., Huelsmann, Erica, Lusciks, Eugene, Hill, G. R

Multispectral imaging and objective assessment of immune-tumor interactions in non-small cell lung cancer

C. Ballesteros-Merino, M. Neuberger, Zipei Feng, R. Huber, J. Stump, Amanda Tufm

The role of BRAF V600 mutation in melanoma

P. Ascierto, J. Kirkwood, J. Grob, E. Simeone, A. Grimaldi, M. Maio, G. Palmieri

Tumor immunologic heterogeneity influences response to radiation and combination immunotherapy

Aguilera, Todd A., Rafat, Marjan, Kariolis, Mihalis S., Eyben, Rie von, Graves,

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfu

B. Horton, Jason B. Williams, S. Spranger, T. Gajewski

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyt

Elsas, Andrea van, Hurwitz, Arthur A., Allison, James P.

Combination immunotherapy approaches.

Drake, C G

Abstract 2858: Radiation and dual immune checkpoint blockade overcome tumor resistance and distinctly improve immunity

Rech, Andrew J., Victor, Christina Twyman-Saint, Maity, Amit, Rengan, Ramesh, Pa

Abstract PR05: Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo

Das, Rituparna, Verma, Rakesh, Sznol, Mario, Boddupalli, Chadra Sekhar, Gettinge

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Quezada, Sergio A.

Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blo

Klyushnenkova, Elena N; Riabov, Vladimir B; Kouiavskaia, Diana V et al.

Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immu

Sckisel, Gail D; Mirsoian, Annie; Bouchlaka, Myriam N et al.

Immune checkpoint combinations from mouse to man.

Ai, Midan; Curran, Michael A

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.

Martin, Kea; Müller, Philipp; Schreiner, Jens et al.

Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination wit

Dos Santos, Luara Isabela; Galvão-Filho, Bruno; de Faria, Paula Cristina et al.

Combining Vaccines with Conventional Therapies for Cancer.

Arlen, Philip M; Madan, Ravi A; Hodge, James W et al.

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

Vanpouille-Box, Claire; Pilones, Karsten A; Wennerberg, Erik et al.

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune

Zhu, J; Zou, L; Zhu, S et al.

The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

Schwager, Kathrin; Hemmerle, Teresa; Aebischer, David et al.

Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Kwek, Serena S; Cha, Edward; Fong, Lawrence

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

Engeland, Christine E; Grossardt, Christian; Veinalde, Rūta et al.

Combination therapy of immunocytokines with ipilimumab: a cure for melanoma?

Wang, Tao; Somasundaram, Rajasekharan; Herlyn, Meenhard

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eroglu, Zeynep; Kim, Dae Won; Wang, Xiaoyan et al.

Ipilimumab (Yervoy) and the TGN1412 catastrophe.

Bakacs, Tibor; Mehrishi, Jitendra N; Moss, Ralph W

The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants.

Thangavelu, Govindarajan; Murphy, Kenneth M; Yagita, Hideo et al.

Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.

Bakacs, Tibor; Mehrishi, Jitendra N

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

Blank, Christian U

CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor

Son, Cheol-Hun; Bae, Jae-Ho; Shin, Dong-Yeok et al.

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

Soares, Kevin C; Rucki, Agnieszka A; Wu, Annie A et al.

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Mangsbo, Sara M; Sandin, Linda C; Anger, Kerstin et al.

Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-tar

Sundstedt, Anette; Celander, Mona; Eriksson, Helena et al.

Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats estab

Agarwalla, Pankaj; Barnard, Zachary; Fecci, Peter et al.

Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.

Danlos, François-Xavier; Pagès, Cécile; Roux, Jennifer et al.

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from convent

Pennock, Gregory K; Waterfield, William; Wolchok, Jedd D

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Spigel, David R; Socinski, Mark A

Dose-dependent effect of anti-CTLA-4 on survival in sepsis.

Inoue, Shigeaki; Bo, Lulong; Bian, Jinjun et al.

Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of den

Saha, Asim; Chatterjee, S K

Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.

Lesterhuis, W Joost; Salmons, Joanne; Nowak, Anna K et al.

Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by

Yoshimoto, Yuya; Suzuki, Yoshiyuki; Mimura, Kousaku et al.

Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge.

Hirao, Lauren A; Hokey, David A; Morrow, Matthew P et al.

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferati

Curran, Michael A; Kim, Myoungjoo; Montalvo, Welby et al.

[Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma].

Krajsová, I

Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.

Nicholas, Sarah; Mathios, Dimitris; Ruzevick, Jacob et al.

Managing immune checkpoint-blocking antibody side effects.

Postow, Michael A

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.

Chow, Laura Q M

Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch, Jamie; Cheadle, Eleanor J; Dovedi, Simon J et al.

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.

Momtaz, Parisa; Postow, Michael A

Immunotherapy for malignant melanoma.

Zeiser, Robert; Schnitzler, Marc; Andrlova, Hana et al.

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

Dai, Min; Yip, Yuen Yee; Hellstrom, Ingegerd et al.

Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basi

Sun, Jingjing; Tang, Derek Ng; Fu, Tihui et al.

CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy

Wu, Licun; Yun, Zhihong; Tagawa, Tetsuzo et al.

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic

Müller, Philipp; Martin, Kea; Theurich, Sebastian et al.

Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.

Pentcheva-Hoang, Tsvetelina; Simpson, Tyler R; Montalvo-Ortiz, Welby et al.

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rha

Min, Le; Hodi, F Stephen

Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Harshman, Lauren C; Drake, Charles G; Wargo, Jennifer A et al.

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

Lines, J Louise; Sempere, Lorenzo F; Broughton, Thomas et al.

Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

Sitkovsky, Michail V; Hatfield, Stephen; Abbott, Robert et al.

CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

Chen, Hong; Fu, Tihui; Suh, Woong-Kyung et al.

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in

Avogadri, Francesca; Zappasodi, Roberta; Yang, Arvin et al.

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Callahan, Margaret K; Masters, Gregg; Pratilas, Christine A et al.

Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.

Zippelius, Alfred; Schreiner, Jens; Herzig, Petra et al.

Immunotherapies in Early and Advanced Renal Cell Cancer.

Kasenda, Benjamin; Larkin, James; Gore, Martin

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.

Buchbinder, Elizabeth; Hodi, F Stephen

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber, Jeffrey

Immune checkpoint blockade in patients with melanoma metastatic to the brain.

Di Giacomo, Anna Maria; Margolin, Kim

Toxicity patterns with immunomodulating antibodies and their combinations.

Haanen, John B A G; Thienen, Hans van; Blank, Christian U

Therapeutic combinations of immune-modulating antibodies in melanoma and beyond.

Cohen, Justine; Sznol, Mario

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, James; Chiarion‐Sileni, Vanna; González, René et al.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, James; Chiarion‐Sileni, Vanna; González, René et al.

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Yu, Ping; Steel, Jason C; Zhang, Meili et al.

Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Snyder, Alexandra; Makarov, Vladimir; Merghoub, Taha et al.

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.

Kim, KiBem; Skora, Andrew D; Li, Zhaobo et al.

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antige

Kwon, E D; Foster, B A; Hurwitz, A A et al.

Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.

Okita, Riki; Yamaguchi, Yoshiyuki; Emi, Akiko et al.

Therapy of metastatic malignant melanoma: on the way to individualized disease control.

Vogt, Thomas

[Side effects of Modern Immunotherapy and How to Solve Them in the Clinics].

Lakomý, R; Poprach, A

Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.

Postow, Michael A; Harding, James; Wolchok, Jedd D

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Ruocco, Maria Grazia; Pilones, Karsten A; Kawashima, Noriko et al.

Update on immune checkpoint inhibitors in lung cancer.

Creelan, Benjamin C

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.

Wada, Satoshi; Jackson, Christopher M; Yoshimura, Kiyoshi et al.

Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal seps

Chang, Katherine C; Burnham, Carey-Ann; Compton, Stephanie M et al.

To be, or not to be immunocompetent.

Volk, Hans-Dieter; Reinke, Petra

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metasta

Masucci, Giuseppe V; Wersäll, Peter; Kiessling, Rolf et al.

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

Läubli, Heinz; Balmelli, Cathrin; Bossard, Matthias et al.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer, Andrew M; Thompson, Craig B

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against m

Simpson, Tyler R; Li, Fubin; Montalvo-Ortiz, Welby et al.

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.

Fan, Xiaozhou; Quezada, Sergio A; Sepulveda, Manuel A et al.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard, Rikke B; Zamarin, Dmitriy; Munn, David H et al.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung c

Zielinski, C; Knapp, S; Mascaux, C et al.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips, George K; Atkins, Michael

Therapeutic use of anti-CTLA-4 antibodies.

Blank, Christian U; Enk, Alexander

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial g

Pedersen, A E; Buus, S; Claesson, M H

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Shin, Daniel Sanghoon; Ribas, Antoni

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney, Kathleen M; Freeman, Gordon J; McDermott, David F

Orchestrating immune check-point blockade for cancer immunotherapy in combinations.

Perez-Gracia, Jose Luis; Labiano, Sara; Rodriguez-Ruiz, Maria E et al.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and an

Simeone, Ester; Ascierto, Paolo A

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.

Kong, Yi-Chi M; Flynn, Jeffrey C

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou, Marie; Pitt, Jonathan M; Daillère, Romain et al.

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Hu-Lieskovan, Siwen; Mok, Stephen; Homet Moreno, Blanca et al.

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

Müller, Philipp; Kreuzaler, Matthias; Khan, Tarik et al.

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Cha, Edward; Klinger, Mark; Hou, Yafei et al.

Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyin

Vaccari, Monica; Boasso, Adriano; Fenizia, Claudio et al.

Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.

Waitz, Rebecca; Solomon, Stephen B; Petre, Elena N et al.

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

Duraiswamy, Jaikumar; Kaluza, Karen M.; Freeman, Gordon J. et al.

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive m

Williams, Emily L; Dunn, Stuart N; James, Sonya et al.

Prospects for TIM3-Targeted Antitumor Immunotherapy.

Ngiow, Shin Foong; Teng, Michele W L; Smyth, Mark J

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.

Marabelle, Aurélien; Kohrt, Holbrook; Levy, Ronald

Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleuk

Yu, Ping; Steel, Jason C; Zhang, Meili et al.

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui, Jun; Nishikawa, Hiroyoshi; Muraoka, Daisuke et al.

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Allard, Bertrand; Pommey, Sandra; Smyth, Mark J et al.

Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!

Castro, Maria G; Baker, Gregory J; Lowenstein, Pedro R

Immune checkpoint modulation for non-small cell lung cancer.

Soria, Jean-Charles; Marabelle, Aurélien; Brahmer, Julie R et al.

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulato

Liu, Li; Mayes, Patrick A; Eastman, Stephen et al.

Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor ly

Kawano, Masanori; Itonaga, Ichiro; Iwasaki, Tatsuya et al.

Immune checkpoint inhibitors: therapeutic advances in melanoma.

Márquez-Rodas, Ivan; Cerezuela, Pablo; Soria, Ainara et al.

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Olson, Brian M; Jankowska-Gan, Ewa; Becker, Jordan T et al.

Predictive factors for immunotherapy in melanoma.

Teixidó, Cristina; González-Cao, Maria; Karachaliou, Niki et al.

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.

Kwek, Serena S; Dao, Vinh; Roy, Ritu et al.

Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived

Motoshima, Takanobu; Komohara, Yoshihiro; Horlad, Hasita et al.

Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation a

Pedicord, Virginia A; Cross, Justin R; Montalvo-Ortiz, Welby et al.

Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance.

Schwarz, A; Beissert, S; Grosse-Heitmeyer, K et al.

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Das, Rituparna; Verma, Rakesh; Sznol, Mario et al.

An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.

Loser, Karin; Scherer, Andrea; Krummen, Mathias B W et al.

Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.

Jovasevic, Vladimir M; Gorelik, Leonid; Bluestone, Jeffrey A et al.

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

Keler, Tibor; Halk, Ed; Vitale, Laura et al.

ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.

Riley, J L; Blair, P J; Musser, J T et al.

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

Hooijkaas, Anna; Gadiot, Jules; Morrow, Michelle et al.

Cancer immunology - development of novel anti-cancer therapies.

Rothschild, Sacha I; Thommen, Daniela S; Moersig, Wolfgang et al.

Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate canc

Li, F; Guo, Z; Yu, H et al.

Immune checkpoint inhibitors in NSCLC.

Johnson, Douglas B; Rioth, Matthew J; Horn, Leora

New therapeutic targets in melanoma.

Martí, R M; Sorolla, A; Yeramian, A

Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a mur

Sorensen, Maria R; Holst, Peter J; Steffensen, Maria A et al.

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.

Cao, K; Wang, G; Li, W et al.

Radiotherapy Combined with Immune Checkpoint Inhibitor on Murine Fibrosarcoma and a Narrative Review of Clinical Studies

Kim, Wonwoo, Kim, Hyunkyung, Jang, Won Il, Kim, Mi Sook, Bae, Sun Hyun

Impact of adding immune checkpoint inhibitors to standard therapies in non-small cell lung cancer: A systematic review o

Correia, Ana Pinto, Marques, Adriana, Sepodes, Bruno, Torre, Carla, Rocha, João

Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using secon

Adashek, Jacob J, Genovese, Giannicola, Tannir, Nizar M, Msaouel, Pavlos

Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?

Plas, Stefan, Pircher, Andreas, Heidegger, Isabel

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Car

Xing, Daniel Tao, Khor, Richard, Gan, Hui, Wada, Morikatsu, Ermongkonchai, Tai,

Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms

Connor K. Sisk, Laci M. Turner, Shafkat Meraj, Nabiha Yusuf

Novel therapeutic strategies for non-small cell lung cancer: Combination therapies with immune checkpoint inhibitors (Re

Ma, Shengyao, Hu, Ruixin, Xue, Xiaobin, Qu, Meihua, Sun, Guoping

Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms

Sundström, E., Huang, Xueting, Wiemer, Andrew J.

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Stratigos, Alexander, Garbe, Claus, Dessinioti, Clio, Lebbé, Célèste, Bataille,

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Raskov, Hans, Orhan, Adile, Christensen, Jan Pravsgaard, Gögenür, Ismail

A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future

Esfahani, Khashayar, Roudaia, Liya, Buhlaiga, Najwa, Rincón, Sonia V. del, Papne

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma

Bersanelli, Melissa, Rebuzzi, Sara Elena, Roviello, Giandomenico, Catalano, Mart

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.

Li, Jiarui; Kan, Haoxuan; Zhao, Lin et al.

Cancer immunotherapy: the beginning of the end of cancer?

Farkona, Sofia, Diamandis, Eleftherios P., Blasutig, Ivan M.

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Tang, Yujun, Liu, Jiajia, Zhang, Dingyi, Xu, Zhenghao, Ji, Jinjun, Wen, Chengpin

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.

Zheng, Qingyue; Li, Jiarui; Zhang, Hanlin et al.

Comprehensive review of targeted therapy for colorectal cancer

Xie, Yuanhong, Chen, Yingxuan, Fang, Jing‐Yuan

Development of therapeutic antibodies for the treatment of diseases

Lu, Ruei‐Min, Hwang, Yu‐Chyi, Liu, I-Ju, Lee, Chi‐Chiu, Tsai, Han-Zen, Li, Hsin‐

The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.

Marchand, Lucien; Disse, Emmanuel; Dalle, Stéphane et al.

The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systemati

Tian, Yuan; Li, Ran; Liu, Yan et al.

Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis.

Zhang, Tian; Wang, Yi; Shi, Chunhui et al.

Health-Related Quality of Life in the Era of Immune Checkpoint Blockade: What Do Patient-Reported Outcomes Reveal?

Dunker, Alexandra M; Malik, Neha; Krause, Kathryn J et al.

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer

Song, Dandan, Hou, Shufu, Ma, Ning, Yan, Bing, Gao, Jing

Emerging immunotherapy and tumor microenvironment for advanced sarcoma: a comprehensive review.

Huang, Hai, Fan, Yiwei, Zhang, Shuling, Bai, Xueli, Wang, Xiaonan, Shan, Fengpin

The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresect

Pu, Wenji, Li, Shasha, Zhang, Jinliang, Huang, Jijie, Li, Jishi, Jiang, Yong, Xu

Case Report: When dual immune checkpoint blockade strikes back: cadonilimab-induced hypersensitivity in solid tumors - a

Song, Ping, Jin, Yuqi, Fu, Linglin, Yang, Fengming, Tan, Yinuo

Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis.

Ye, Minyan; Dong, Yinuo; Li, Xiaoyun et al.

Incidence of pneumonitis with CTLA-4 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.

Li, Wei, Xiong, Hao, Peng, Haiying, Yang, Ting, Fan, Li, Zhang, Yanlin

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer.

Yang, Hui, Wang, Kunlun, Wang, Tao, Li, Mengxi, Li, Bingxu, Li, Shenglei, Yuan,

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastat

Pacheco, Jose M., Camidge, D. Ross, Doebele, Robert C., Schenk, Erin L.

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer.

Oliveira, André F, Bretes, Luís, Furtado, Irene

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung C

Liang, Xiuju, Guan, Yaping, Zhang, Bicheng, Liang, Jing, Wang, Baocheng, Li, Yan

The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1

Tian, Yuan, Zhang, Zewen, Yang, Xiaowei, Li, Donghua, Zhang, Li, Li, Zhuoqi, Zha

Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review a

Liu, Hongmei; Xu, Dongmei; Wang, Wentao et al.

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Me

Hu, Jiexuan, Tian, Ruyue, Ma, Yingjie, Zhen, Hongchao, Ma, Xiao, Su, Qiang, Cao,

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment.

Altaf, Reem, Jadoon, Sarmad Sheraz, Muhammad, Syed Aun, Ilyas, Umair, Duan, Yong

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcom

Seong, Gyuhee, D’Angelo, Sandra P.

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small ce

Chen, Chunlan, Tian, Peng, Zhong, Jiangshan, Fan, Xianming

Data Sheet 1_Comparative effectiveness and safety of immunotherapeutic strategies in ovarian cancer: a systematic review

(10068460), Xinyao Wang, (11716952), Yuli Zhang, (16543), Wei Xie, (135547), Hai

Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.

Man, Johnathan, Ritchie, Georgia, Links, Matthew, Lord, Sally, Lee, Chee Khoon

Comparative effectiveness and safety of immunotherapeutic strategies in ovarian cancer: a systematic review and network

Wang, Xinyao, Zhang, Yuli, Xie, Wei, Liu, Haiying, Cui, Lianghui, Feng, Min

PD-1/PD-L1 Inhibitors in Cervical Cancer.

Liu, Yuncong, Wu, Li, Tong, Ruizhan, Yang, Feiyue, Yin, Limei, Li, Mengqian, You

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Met

Ge, Yang, Zhang, Huiyun, Weygant, Nathaniel, Yao, Jiannan

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and M

Yang, Yi, Jin, Gang, Pang, Yao, Huang, Yijie, Wang, Wenhao, Zhang, Hongyi, Tuo,

The non-classical immune checkpoint HLA-G: a regulatory master switch governing tolerance, evasion, and translational fr

Huan Liu, Qiong Li, Junli Li, Ying Xue, Xiaofei Xue, Pingping Xu

Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for exte

Shuang Zhang, Shuang Li, Ying Cheng

Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized cl

Peng, Tzu-Rong, Wu, Ta-Wei

Chemoimmunotherapy versus immune checkpoint inhibitors monotherapy as first‐line treatment for advanced non‐small cell l

A. Rizzo

Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-

Wang, Liming, Yang, Yifan, Yu, Jiangyong, Zhang, Shuai, Li, Xu, Wu, Xiaonan, Nie

Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-

Shen, Xiang, Huang, Shangke, Xiao, Hua, Zeng, Shan, Liu, Jiexing, Ran, Zhuolan,

Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF ag

Feng, Zhichao, Rong, Pengfei, Wang, Wei

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-s

Zhou, Fei, Zhao, Wencheng, Gong, Xiaomei, Ren, Shengxiang, Su, Chunxia, Jiang, T

Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.

Zhang, Meilin, Song, Jian, Yang, Hongguang, Jin, Feng, Zheng, Ang

Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analy

Ninomiya, Kiichiro, Oze, Isao, Kato, Yuka, Kubo, Toshio, Ichihara, Eiki, Rai, Ka

Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review.

Wang, Hanxun, Song, Peilu, Gao, Yinli, Shen, Lanlan, Xu, Hanqin, Wang, Jian, Che

Research advances in immune checkpoint drugs for non-small cell lung cancer.

Shen, Yue, Chen, Juan, Li, Xiang-Ping

Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and

Hou, Yan-Li, Wang, Di-Ya, Hu, Jie-Xuan, Tian, Ru-Yue, Wang, Wei, Su, Qiang, Li,

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic

Di Lorenzo, Giuseppe, De Placido, Sabino, Pagliuca, Martina, Ferro, Matteo, Luca

Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.

Jamy, Omer, Sonpavde, Guru

Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systemat

Feng, Yuqian, Guo, Kaibo, Jin, Huimin, Jiang, Jing, Wang, Menglei, Lin, Shengyou

Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systema

Noori, Maryam, Fayyaz, Farimah, Zali, Mohammad Reza, Bashash, Davood

Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated wit

Zheng, Qi-Ming, Li, Yuan-Yuan, Wang, Ye-Peng, Li, Guo-Xiang, Zhao, Meng-Meng, Su

PD-1/PD-L1 inhibitors in endometrial cancer with high microsatellite instability: a Kaplan-Meier-derived patient data me

de Moraes, Francisco Cezar Aquino, Cavalcanti Souza, Maria Eduarda, Rodrigues Ca

Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strateg

Zhang, Yi, Li, Zheng, Huang, Ying, Xu, Yong, Zou, Bingwen

Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.

Samimi, Mahtab

From cold to hot tumors: feasibility of applying therapeutic insights to TNBC.

Yan, Shaozhang, Sun, Xinyue, Wang, Kuanyu

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

Farina, Matthew S; Lundgren, Kevin T; Bellmunt, Joaquim

Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-a

Zhang, Xiao, Yang, Zhengyang, An, Yongbo, Liu, Yishan, Wei, Qi, Xu, Fengming, Ya

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.

Huang, Shuang, Zheng, Gang, Yang, Kai

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Long, Junyu, Lin, Jianzhen, Wang, Anqiang, Wu, Liangcai, Zheng, Yongchang, Yang,

Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions

Li, Yueyi, Shen, Li, Jiang, Zedong, Tan, Keqin, Meng, Yuanling, Zhang, Dingyi, M

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Pan, Chong-xian, Liu, Hongtao, Robins, Elizabeth, Song, Wenru, Liu, Delong, Li,

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.

Wang, Dongxu, Lin, Jianzhen, Yang, Xu, Long, Junyu, Bai, Yi, Yang, Xiaobo, Mao,

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Anal

Dammeijer, Floris, Lievense, Lysanne A., Veerman, G., Hoogsteden, Henk C., Hegma

Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small

R. Pathak, G. Lopes, Han Yu, Wenyan Ji, M. Aryal, K. Frumento, C. Wallis, Z. Kla

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1

Feng, Yuqian, Jin, Huimin, Guo, Kaibo, Xiang, Yuying, Zhang, Yiting, Du, Wurong,

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic r

Zeng, Siyuan, Liu, Daju, Yu, Yongai, Zou, Lei, Jin, Xianyu, Liu, Bing, Liu, Life

A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated

Lin, Li; Xiao, Lu; Li, Lei et al.

Association between immune check point inhibitors and digestive system inflammatory adverse reactions: evidence from pha

Zou, Ya, Li, Qinchuan, Zhou, Lu, Lu, Yun, Wei, Hua, Zhou, Yan, Lin, Shibo, Guo,

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review

Viscardi, Giuseppe, Vitiello, Fabiana, Servetto, Alberto, Gristina, Valerio, Piz

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.

Chick, Robert Connor, Gunderson, Andrew J, Rahman, Shafia, Cloyd, Jordan M

Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

Lee, Aaron M., Weaver, Alice N., Acosta, Phillip, Harris, Lauren, Bowles, Daniel

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.

Mao, Chenkai, Poimenidou, Maria, Craig, Brian T

A Comprehensive Review of Immunotherapeutic Modalities in Glioblastoma: Mechanisms, Efficacy, and Safety Considerations

Agarwal, Savi, Han, Simon, Lal, Aadi, Vira, Viranshi, Chandla, Anubhav, Mehranpo

A comprehensive review of immune checkpoint inhibitors for cancer treatment.

Arafat Hossain, Md

The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-a

Mo, Dun-Chang, Huang, Jian-Feng, Luo, Peng-Hui, Huang, Shang-Xiao, Wang, Han-Lei

P1.11.42 Dual Immune Checkpoint Blockade With CTLA-4 and PD-(L)1 Inhibitors in NSCLC: A Reconstructed Patient Data Meta-

Federico, Alessandro Di, Stumpo, Sara, Mantuano, Francesco, Giglio, Andrea De, B

The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A sy

Wang, Bi-Cheng, Cao, Ru-Bo, Fu, Chen, Chen, Wang-Bing, Li, Pin-Dong, Lin, Guo-He

Salvage nivolumab plus ipilimumab after prior PD-1/PD-L1 inhibitor treatment in metastatic renal cell carcinoma: A meta-

M. Yin, Sherry Mori-Vogt, M. Hinkley, A. Parikh, Yuanquan Yang, K. Collier, A. M

Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis.

Liu, Huiyi; Fu, Lu; Jin, Shuyu et al.

Educational Review: Neoadjuvant Approaches to Melanoma.

Sharon, Cimarron E, Karakousis, Giorgos C

Recent advances in Merkel cell carcinoma.

Robinson, Caitlin G, Tan, Daniel, Yu, Siegrid S

Hepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis.

Lu, Yuping, Lin, Jing, Lu, Yufeng, Lin, Luping, Zheng, Shicheng, Chen, Yu, Huang

The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung ca

Kang, Jing, Zhang, Jun, Tian, Zongsheng, Xu, Ye, Li, Jiangbi, Li, Mingxian

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Wang, Dong-Rui, Wu, Xian-Lin, Sun, Ying-Li

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.

Li, Xiaolei, Shao, Changshun, Shi, Yufang, Han, Weidong

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.

Shen, Ke-Yu, Zhu, Ying, Xie, Sun-Zhe, Qin, Lun-Xiu

Comparative efficacy and safety of prolgolimab + nurulimab and nivolumab + ipilimumab in the first-line therapy of metas

Alexander A. Fedenko, Mariya V. Sedova, A. Kolomeytseva, M. Batov, O. Mironenko,

Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.

Jian, Yuli, Yang, Kangkang, Sun, Xiaoxin, Zhao, Jun, Huang, Kai, Aldanakh, Abdul

Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

Wu, Yuanlin, Yu, Guangmao, Jin, Ketao, Qian, Jun

Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review.

Hu, Guangqiang, Li, Zeng, Chen, Yongji, Liao, Hong, Zhou, Shukui

Immuno-Oncology: Emerging Targets and Combination Therapies.

Marshall, Henry T, Djamgoz, Mustafa B A

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.

Zhang, Huixin, Houadj, Lysa, Wu, Kevin Y, Tran, Simon D

Advances in targeted therapy and immunotherapy for melanoma (Review)

Qin, Ziyao, Zheng, Mei

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.

Tsiouprou, Ioanna, Zaharias, Athanasios, Spyratos, Dionisios

Combination therapies for the treatment of advanced melanoma: a review of current evidence.

Voskoboynik, Mark, Arkenau, Hendrik-Tobias

Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta

Yang, Xiaojun, Zeng, Yihong, Tan, Qinquan, Huang, Zhihua, Jia, Jun, Jiang, Guanm

A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer.

Wang, Chaoyang

Immunotherapy and Antivascular Targeted Therapy in Patients' Treatment with Concurrent Malignant Tumors after Organ

Shen, Bairu; Guo, Zi; Huang, Peng et al.

Efficacy and Safety of Combination Therapy With Immune Checkpoint Inhibitors and Chemotherapy With Gemcitabine and Nab-P

Sohrabi, Hanye; Ghavam, Seyed Mohammad; Azadnajafabad, Sina et al.

Clinical Benefits of Combination Immunotherapy Over Standard Immunotherapy Monotherapy in Previously Treated Advanced Es

Chen, Yong, Chen, Zixuan, Guo, Hong, Zhou, Heng, Deng, Yizhou, Wang, Rui, Han, F

The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhi

Yang, Yao, Chen, Dongbo, Zhao, Bigeng, Ren, Liying, Huang, Rui, Feng, Bo, Chen,

Immunotherapy for resectable lung cancer

Dennehy, Colum, Conroy, Michael R., Forde, Patrick M.

The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and sa

Wu, Yingcheng, Shi, Hui, Jiang, Maorong, Qiu, Mingyan, Jia, Keren, Cao, Tianyue,

Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors.

Li, Zhiyang, Wu, Xin, Zhao, Yanjie, Xiao, Yinan, Zhao, Yunuo, Zhang, Ting, Li, H

The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.

Ziogas, Ioannis A, Evangeliou, Alexandros P, Giannis, Dimitrios, Hayat, Muhammad

Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges.

Sheela, I Jeya, Jeya Ranchani, A Amala, Murali, Aravindh, Premkumar, H

Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized co

Mo, Dun-Chang, Huang, Jian-Feng, Luo, Peng-Hui, Huang, Shang-Xiao, Wang, Han-Lei

An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.

Castellano, Tara, Moore, Kathleen N, Holman, Laura L

Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art.

Le Saux, Olivia, Lounici, Yasmine, Wajda, Pauline, Barrin, Sarah, Caux, Christop

Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review.

Miao, Kang, Zhang, Li

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.

Abdel-Rahman, Omar

Benefits and risks of PD-1/PD-L1 inhibitors for recurrent small cell lung cancer: A systematic review and meta-analysis.

Zhou, Juyue, Du, Zhonghai, Liang, Yan, Zhang, Sensen

Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis.

Wei, Yuhan, Du, Qi, Jiang, Xiaoyue, Li, Li, Li, Teng, Li, Mengqi, Fan, Xueke, Li

A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.

Martorana, F, Colombo, I, Treglia, G, Gillessen, S, Stathis, A

Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents

Oresti, Sara; Salomone, Fabio; Nuccio, Antonio et al.

Primary urethral melanoma treated sucessfully with wide excision and combination immunotherapy: Case report and review o

Martinez, Mariela, Kotamarti, Srinath, Schulman, Ariel, Mooppan, Unni, Wang, Jen

Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.

Zhang, Bo; Tao, Baorui; Li, Yitong et al.

Combination immunotherapy in a patient with hemodialysis therapy and metachronous bilateral clear cell renal cell carcin

Isaza, Alejandro Pineda, Franco, Alvaro Osorio, Quintero González, Lisceth Paola

Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of random

Zhang, Bo, Wu, Qiong, Zhou, You Lang, Guo, Xinyu, Ge, Jun, Fu, Jiaji

Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanom

Zhang, Bo; Zhou, You Lang; Chen, Xinming et al.

Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepat

Zheng, Jiaxi, Shao, Minghai, Yang, Weifang, Ren, Justin, Chen, Xiaofeng, Yang, H

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Canc

Ge, Yanjun; Zhang, Yuchen; Zhao, Kong-Nan et al.

Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options

Koulouris, Andreas, Tsagkaris, Christos, Spyrou, V., Pappa, Eleni V., Troullinou

A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.

Wan, Ning; Ji, Bo; Li, Jian et al.

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-an

Jiang, Yi, Zhang, Ning, Pang, Hailin, Gao, Xiaobo, Zhang, Helong

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis.

Jin, Chunhui; Zhu, Xiaodan; Huang, Xiaona et al.

PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta

Li, Jing, Gu, Jian

PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.

Abdel-Rahman, Omar

The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.

Chen, Rui-Lian, Zhou, Jing-Xu, Cao, Yang, Li, Sui-Hui, Li, Yong-Hao, Jiang, Mei,

Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.

Liu, Wenjie, Huo, Gengwei, Chen, Peng

Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.

Xu Zhou, Jiasheng Cao, Win Topatana, Tian-Ao Xie, Tian-Bin Chen, Jiahao Hu, Shij

Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis.

Huo, Gengwei, Liu, Wenjie, Zhang, Sipei, Chen, Peng

A meta-analysis of application of PD-1/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negat

Zhang, Wei, He, Yujing, Tang, Yuning, Dai, Wei, Si, Yuexiu, Mao, Feiyan, Xu, Jia

Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.

Abdel-Rahman, Omar

Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A System

Han, Lei, Li, Guangxin, Li, Huihui, Zhao, Lei

A Complete Response to Combined Immunotherapy in a Patient with an ATM plus SF3B1 Mutation and a Moderate Tumor Mutation

Ferreira Bruzzi Porto, Helena, C K Lopes, Gabriela, B V Bekierman, Hannah, Altin

First-Line Dual Immune Checkpoint Inhibition with PD-1/PD-L1 and CTLA-4 Blockade for Advanced Non-Small Cell Lung Cancer

Xu, Wenqing, Niu, Chuyuan

Prognostic Significance of CD4+ Tumour Infiltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD

Zheng, Qi-Ming, Li, Yuan-Yuan, Wang, Ye-Peng, Li, Guo-Xiang, Sun, Zhi-Gang, Zhan

Correlation of Peripheral Blood CD4/CD8 Ratio with Efficacy and Prognosis in Patients with Non-Small Cell Lung Cancer Re

Li, Guo-Xiang, Zheng, Qi-Ming, Li, Yuan-Yuan, Wang, Ye-Peng, Zhang, Min, Sun, Zh

Severe Bone Marrow Hypoplasia in a Combined Treatment with Anti PD 1/CTLA-4 in a Patient with Melanoma: A Case Report an

Zoppi, M.

Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic

Zhen-Yu Li, Zhen Zhang, Xiaozhong Cao, Yun Feng, Shasha Ren

Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy

Mandy van Gulijk, Floris Dammeijer, J. Aerts, H. Vroman

The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma.

Amin, Asim, Hammers, Hans

IL-15 in the Combination Immunotherapy of Cancer

Waldmann, Thomas A., Dubois, Sigrid, Miljković, Miloš D., Conlon, Kevin C.

Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advan

Xu, Qian, Zhang, Xue, Huang, Miao, Dai, Xin, Gao, Jing, Li, Song, Sheng, Lei, Hu

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patie

Li, Jiayi, Zhang, Xin, Mu, Zhuanzhuan, Sun, Di, Sun, Yuqing, Lin, Yansong

Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-ana

Feng, Yuqian, Guo, Kaibo, Jin, Huimin, Jiang, Jing, Wang, Menglei, Lin, Shengyou

Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta

Zhang, Chi, Wei, Fengtao, Ma, Wenhan, Zhang, Jingbo

Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-n

Qian, Xiao, Ning, Weihai, Dunmall, Louisa Chard, Qu, Yanming, Wang, Yaohe, Zhang

Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis

Sisodiya, Sandeep, Kasherwal, Vishakha, Rani, Jyoti, Mishra, Neetu, Kumar, Sande

Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?

Sabanathan, Dhanusha; Park, John J; Marquez, Manuel et al.

Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review an

Cui, Wei, Luo, Qing, Sun, Si-Lu, Xu, Jun-Lin, Gu, Hong

Advances in immunotherapy for HNSCC

Lin Dong, Haixia Xu, Xionghao Pang, Yiqian Liu, Meixiang Li

Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed

Salama, Moschos

Иммунотерапия уротелиального рака: реалии и перспективы

M. I. Volkova, Ya. V. Gridneva, A. S. Ol’shanskaya

Efficiency in different immunotherapy of cancer: literature review

K. A. Gaptulbarova, M. Tsyganov, M. Ibragimova, A. Pevzner, L. V. Spirina, N. Li

Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.

Hu, Hao, Zhu, Qian, Luo, Xian Shi, Yang, Xiong Wen, Wang, Hai Dong, Guo, Chang Y

Recent Developments of Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative

Battogtokh, Gantumur, Obidiro, Onyinyechi, Akala, Emmanuel O.

Immune Cytolytic Activity and Strategies for Therapeutic Treatment

Agioti, Stephanie, Zaravinos, Apostolos

Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative revie

Wang, Nuo-Han, Lei, Zheng, Yang, Hao-Nan, Tang, Zheng, Yang, Mengqi, Wang, Ying,

A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined tr

Lan, Tianhang, Ran, Shengming, Gao, Mingchao, Li, Wenjie, He, Wang

The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis.

Xiao, Bo-Ya, Lin, Guo-He, Zhao, Yan-Xia, Wang, Bi-Cheng

First-line treatment of extensive-stage small cell lung cancer with immune checkpoint inhibitors acting on different tar

Meng Li, Yu-zhu Chen, Dazhong Chen, Yang Wang, Hong-Li Zhao

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review.

Liu, Yu, Chen, Peixin, Wang, Hao, Wu, Shengyu, Zhao, Sha, He, Yayi, Zhou, Caicun

Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy

Hendriks, Lizza, Rouleau, Étienne, Besse, Benjamin

Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?

Peng, Ling, Stebbing, Justin, Liang, Fei, Xia, Yang

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level m

Passiglia, Francesco, Galvano, Antonio, Gristina, Valerio, Barraco, Nadia, Casti

Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer

T. Veen, A. Kanani, D. Lea, K. Søreide

Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta

Tan, An-Ju, Mo, Dun-Chang, Wu, Ka, Pan, Hong-Mei, Wang, Dong-Mei, Xu, Xing-Xin,

PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.

Wu, Huiming, Deng, Min, Xue, Dingwen, Guo, Renkai, Zhang, Chenyu, Gao, Jiaqi, Li

Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review

Nagai, Hiroki, Muto, Manabu

Kidney injuries related to ipilimumab.

Izzedine, Hassane, Gueutin, Victor, Gharbi, Chems, Mateus, Christine, Robert, Ca

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT,

De Giglio, Andrea, Di Federico, Alessandro, Nuvola, Giacomo, Deiana, Chiara, Gel

Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.

Rao, Quan, Li, Min, Xu, Wei, Pang, Kai, Guo, XiaoBo, Wang, Dong, Liu, Jun, Guo,

PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Tr

de Moraes, Francisco Cezar Aquino, Sano, Vitor Kendi Tsuchiya, Silva, Barbara Li

Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clin

Wang, Bitao, Zhuang, Shaowei, Lin, Shengnan, Lin, Jierong, Zeng, Wanxian, Du, Bi

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Sys

Liao, Pei-Fei, Wang, Ping-Yu, Peng, Tzu-Rong

The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.

Dong, Linyinxue, Tian, Xuechen, Zhao, Yunqi, Tu, Haohong, Wong, Aloysius, Yang,

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte

Mehta, Apoorva, Motavaf, Mateen, Nebo, Ikenna, Luyten, Sophia, Osei-Opare, Kofi

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Dyhl-Polk, Anne, Mikkelsen, Marta Kramer, Ladekarl, Morten, Nielsen, Dorte Lisbe

The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review

Schipilliti, Francesca Matilde, Garajová, Ingrid, Rovesti, Giulia, Balsano, Rita

Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy

Galván-Morales, Miguel Ángel, Rodríguez, Raúl Barrera, Santiago, Julio, Terán, L

Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.

Park, Robin, Eshrat, Fariha, Al-Jumayli, Mohammed, Saeed, Azhar, Saeed, Anwaar

In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity.

Chikovani, Tinatin, Magen, Eli

A review on immune checkpoint blockage therapy

Shajahan, Thamrook s, Dharan, Shaiju S, Nj, Merlin

The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic re

Bishay, K; Tandon, P; Bourassa-Blanchette, S et al.

Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic c

Choucair, Khalil, Radford, Maluki, Bansal, Ajay, Park, Robin, Saeed, Anwaar

Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target t

Rijavec, Erika, Biello, Federica, Barletta, Giulia, Dellepiane, Chiara, Genova,

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

Kong, Xianbin, Lu, Peng, Liu, Chuanxin, Guo, Yuzhu, Yang, Yuying, Peng, Yingying

PD‑1/PD‑L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta‑analysis

Rotundo, Maria, Bagnardi, Vincenzo, Rotundo, Miryam, Comandè, Mario, Zampino, Ma

The multidimensional regulatory network of the PD-1/PD-L1 axis in the esophageal squamous cell carcinoma microenvironmen

Haoyu Lai, Lu Qi, Zhixuan Lin, Zhong Li

Efficacy and safety of lenvatinib combined with PD‑1/PD‑L1 inhibitors in the treatment of hepatocellular carcinoma: A me

Zhang, Baoyan, Su, Linfeng, Lin, Yonghua

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Peng, Tzu-Rong, Yang, Li-Jou, Wu, Ta-Wei

Exploring novel systemic therapies for pancreatic cancer: a review of emerging anti-PD-1/PD-L1 combination therapy

Zhang, He, Duan, Xiao-Rui, Xing, Lu-Yang, Jia, Yu-Xin, Zhou, Jingyi, Ma, Jianjun

Severe cardiac events induced by combination immunotherapy in patients with cancer: a meta-analysis.

Valenzuela-Rodriguez, German, Diaz-Arocutipa, Carlos, Collins, Jaime A, Lopez-Fe

A COMPREHENSIVE REVIEW OF NIVOLUMAB AND IPILIMUMAB COMBINATION THERAPY IN ADVANCED MELANOMA

Subashini, R., Bi, A. Mubina, Roshika, S., Harini, V., Jayasri, S., Sri, S. Pooj

A COMPREHENSIVE REVIEW OF NIVOLUMAB AND IPILIMUMAB COMBINATION THERAPY IN ADVANCED MELANOMA

Subashini, R., Bi, A. Mubina, Roshika, S., Harini, V., Jayasri, S., Sri, S. Pooj

Combining PD-1/PD-L1 and CTLA-4 inhibitors for the treatment of colorectal cancer: A systematic review and meta-analysis

Xiao-hui Fan

Research Status and Future Directions of PD-1/CTLA-4 Bispecific Antibodies in the Treatment of Advanced Hepatocellular C

Bin Zhao

Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens.

Zhao, Lei, Yu, Jing, Wang, Jing, Li, Huihui, Che, Juanjuan, Cao, Bangwei

A Multiaxial Systematic Review On Contemporary Oncotherapeutic Armamentarium And Lobectomy‑Centric Surgical Stratagems I

Dr. Avijit Roy Mondal, Dr. Suhena Sarkar, DrSayani Mondal, Dr Birupaksha Biswas

Reviewer #3 (Public Review): DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer c

J., Mullen Nicholas, K., Shukla Surendra, Ravi, Thakur, Sundeep, Kollala Sai, Wa

Reviewer #2 (Public Review): DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer c

J., Mullen Nicholas, K., Shukla Surendra, Ravi, Thakur, Sundeep, Kollala Sai, Wa

Reviewer #1 (Public Review): DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer c

Mullen, Nicholas J., Shukla, Surendra K., Thakur, Ravi, Kollala, Sai Sundeep, Wa

Reviewer #2 (Public Review): DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer c

Mullen, Nicholas J., Shukla, Surendra K., Thakur, Ravi, Kollala, Sai Sundeep, Wa

Reviewer #1 (Public Review): DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer c

J., Mullen Nicholas, K., Shukla Surendra, Ravi, Thakur, Sundeep, Kollala Sai, Wa

Reviewer #3 (Public Review): DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer c

Mullen, Nicholas J., Shukla, Surendra K., Thakur, Ravi, Kollala, Sai Sundeep, Wa

Primary Malignant Melanoma of the Genitourinary System: A Systemic Review and Report of Eight Cases.

Khayyat, Azadeh, Esmaeil Pour, Mohammad Ali, Mousavi, Seyedreza, Khalili-Toosi,

Mucosal Melanoma: A Rare Entity and Review of the Literature.

Sohal, Raman J, Sohal, Sandeep, Wazir, Ali, Benjamin, Sam

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients

Di Federico, Alessandro, Stumpo, Sara, Mantuano, Francesco, De Giglio, Andrea, L

Shiny-MAGEC: A Bayesian R shiny application for meta-analysis of censored adverse events

Zihan Zhou, Zizhong Tian, C. Peterson, Le Bao, Shouhao Zhou

TIGIT, a novel immune checkpoint therapy for melanoma.

Tang, Wei, Chen, Jun, Ji, Tianlong, Cong, Xiufeng

Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.

Benhima, Nada, Belbaraka, Rhizlane, Langouo Fontsa, Mireille D

Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC.

Luciani, Andrea, Dottorini, Lorenzo, Battaiotto, Elena, Petrelli, Fausto

The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Sy

Tandon, Parul; Bourassa-Blanchette, Samuel; Bishay, Kirles et al.

Efficacy and Safety of Immune Checkpoint Inhibitors on Advanced Cervical Cancer: A Systematic Review and Meta-analysis.

Wang, Wenhui, Bi, Xiaoning, Feng, Ye, Ming, Xue, Saina, Guo, Kun, Wang, Ling, Bi

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known.

Zheng, Caiyun, Huang, Shunmin, Lin, Meimei, Hong, Baohui, Ni, Ruping, Dai, Hengf

Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inh

Ren, Wei, Fang, Yingying, He, Yujing, Ren, Yifeng, Wang, Minfang, Xu, Anyi, Ruan

Toxicities associated with immune checkpoint inhibitors: a systematic study.

Kong, Xiangyi, Chen, Li, Su, Zhaohui, Sullivan, Ryan J, Blum, Steven M, Qi, Zhih

Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinica

Dongxu Wang, Hui Liu, J. Tian, Daolin Zhang, Lun‐Jie Yan, Zi-Niu Ding, Han Li, Y

Comment on ‘Toxicities associated with immune checkpoint inhibitors: A systematic study’

Mohammad-Salar Hosseini, F. Jahanshahlou

Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysi

Yang, Wenwei, Li, Shuquan, Yang, Qingrui

Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer

Zhang, Pei-Pei; Wang, Juan; Ding, Da-Zhi et al.

PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta

He, Runzhi, Zhao, Xiaoling, Liu, Jianmin, Zhou, Yajing, Zhang, Xiaochong, Cheng,

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systemati

Chen, Yafang, Liu, Xiaomei, Hu, Ying, Xia, Lingling

Contemporaneous and upcoming trends in immunotherapy for prostate cancer: review

Samra Saleem, A. Rashid, Sarma Shehzadi, Hassan Mumtaz, Muhammad Saqib, Anan Bse

The efficacy of regorafenib combined with PD-1/PD-L1 inhibitor in advanced or metastatic colorectal cancer: A single arm

Yang, Fan, Li, Dandan, Li, Baozhong, Yang, Ting, Zhang, Xiaoming, Liu, Zhiqiang,

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A

A. A. Adrianto, I. Riwanto, U. Sadhana, D. K. Paramita, H. Setyawan, K. C. Tjand

PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Guo, Luyong, Liang, Jiali, Dai, Wei, Li, Jiayu, Si, Yuexiu, Ren, Wei, Lu, Yan, C

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systemat

Inoue, Takashi, Narukawa, Mamoru

The Role of Surgery in Metastatic Renal Cell Carcinoma in 2024.

Leung, David Kw, Ko, Ivan Ch, Siu, Brian Wh, Wong, Chris Hm, Yuen, Steffi Kk, Ng

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis

Yuegang Li, Yuwei Du, Chi Xue, P. Wu, N. Du, Guolian Zhu, Huimian Xu, Zhi Zhu

Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a

Boegeholz, Jan, Brueggen, C. S., Pauli, Chantal, Dimitriou, Florentia, Haralambi

Neoadjuvant chemoradiotherapy with or without PD-1/PD-L1 inhibitors in locally advanced rectal cancer: a systematic revi

Ansab, Muhammad, Razi, Sepideh, Nisa, Farwa, Araib, Eiman, Rath, Shree, Khan, Iq

PD-1/PD-L1 inhibitors for locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis based on rand

Liu, Xiaohan, Shang, Zhiyuan, Gao, Jiawei, Jiang, Nan, Wang, Jinpeng, Zhou, Dan,

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Huihui Jiang, Aiqun Xu, Wanli Xia, Xingyuan Xia, Pulin Li, Binbin Zhang, Ke Zhu,

Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-ana

Mi, Ze; Zhang, Yunshu; Feng, Zhichao et al.

Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis

Chu, Xianjing, Tian, Wentao, Ning, Jiaoyang, Zhou, Rongrong

CTIM-29. TOXICITY PROFILE OF DUAL IMMUNE CHECKPOINT BLOCKADE IN MELANOMA BRAIN METASTASES: A META-ANALYSIS OF GRADE ≥3 A

Sarfraz, Zouina, Ganiyani, Mohammad Arfat, Mustafayev, Fatma Nihan Akkoç, Mustaf

CTIM-28. INTRACRANIAL AND SYSTEMIC EFFICACY OF DUAL IMMUNE CHECKPOINT BLOCKADE (NIVOLUMAB AND IPILIMUMAB) IN MELANOMA BR

Sarfraz, Zouina, Ganiyani, Mohammad Arfat, Mustafayev, Fatma Nihan Akkoç, Qidwai

The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review

Güven, Deniz Can, Kavgacı, Gözde, Erul, Enes, Syed, Masood Pasha, Magge, Tara, S

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resista

Gim, Gahyun; Kim, Yeseul; Park, Yeonggyeong et al.

Abstract PO1-28-09: Rethinking the value of pathologic complete response rate for the survival outcomes of early triple-

Xiaoying Qiao, Shu Wang, Taobo Hu, Baosheng Liang

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang, Daniel Y; Salem, Joe-Elie; Cohen, Justine V et al.

Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network met

Lin, Guo; Yao, Zhuoran; Kang, Kai et al.

The Safety of Cadonilimab: A Systematic Review and Single-Arm Meta-Analysis.

Zhang, Zhuo; Yu, Jiao; Zhang, Zhiqi et al.

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of ant

Yun, Seongseok; Vincelette, Nicole D; Green, Myke R et al.

Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Anti

Komaki, Y; Komaki, F; Yamada, A et al.

Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?

De Silva, Pushpamali; Aiello, Marco; Gu-Trantien, Chunyan et al.

Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.

Rubio-Infante, Nestor; Ramírez-Flores, Yoel A; Castillo, Elena C et al.

Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic rev

Guzman-Prado, Yuli; Ben Shimol, Jennifer; Samson, Ondrej

The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.

Ghanizada, Mustafa; Jakobsen, Kathrine Kronberg; Grønhøj, Christian et al.

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data

Swanson, Mark S; Sinha, Uttam K

Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and m

Pala, Laura; Pagan, Eleonora; Sala, Isabella et al.

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.

Cuzzubbo, S; Javeri, F; Tissier, M et al.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella, Edgardo D; Ploussard, Guillaume; LeMaoult, Joel et al.

Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity.

Lucas, Minke W; Burton, Elizabeth M; Dimitriadis, Petros et al.

Immune checkpoint inhibitor doublets: Are they beneficial for older patients? A systematic review and meta-analysis.

Dottorini, Lorenzo; Ghidini, Antonio; Deda, Rita et al.

Novel immunotherapeutic approaches in lung cancer: driving beyond programmed death-1/programmed death ligand-1 and cytot

Resuli, Blerina; Kauffmann-Guerrero, Diego

Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report

Zambrana, Francisco; Barbancho, Carmen; Huelves, Miriam et al.

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systemati

Hao, Chunyan; Tian, Jinhui; Liu, Huiling et al.

Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune check

Zhang, Yongchao; Liu, Bozhi; Kotenko, Sergei et al.

Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.

Song, Peng; Zhang, Dingding; Cui, Xiaoxia et al.

Systematic review: colitis associated with anti-CTLA-4 therapy.

Gupta, A; De Felice, K M; Loftus, E V et al.

Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.

Malaty, Michael M; Amarasekera, Anjalee Thanuja; Li, Cindy et al.

Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.

Su, David; Kluger, Harriet; Olino, Kelly

Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.

Fukuda, Izumi

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

Botticelli, Andrea; Onesti, Concetta Elisa; Zizzari, Ilaria et al.

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.

Song, Lanni; Yang, Yixin; Tian, Xuechen

[Endocrinopathies Associated with Immune Checkpoint Inhibitors].

Santos, Maria Joana

Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comp

Xu, Hang; Tan, Ping; Zheng, Xiaonan et al.

Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Repor

Li, Min; Wu, Chenchen; Liu, Yan et al.

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic

Olivares-Hernández, Alejandro; González Del Portillo, Elísabet; Tamayo-Velasco,

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combinatio

Osipov, Arsen; Lim, Su Jin; Popovic, Aleksandra et al.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.

Wanchoo, Rimda; Karam, Sabine; Uppal, Nupur N et al.

Emerging immunotherapies for metastasis.

Edwards, Sarah C; Hoevenaar, Wilma H M; Coffelt, Seth B

Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis.

Saowapa, Sakditad; Polpichai, Natchaya; Siladech, Pharit et al.

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, Joseph F; Jure-Kunkel, Maria N

Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.

Godwin, J Luke; Zibelman, Matthew; Plimack, Elizabeth R et al.

[Immunotherapy for gastroenterological cancer].

Narita, Yukiya; Muro, Kei

Immunotherapy toxicity. Diagnosis and treatment.

Toribio-Vázquez, Carlos; Gómez Rivas, Juan; Yebes, Alvaro et al.

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management.

Shivaji, Uday N; Jeffery, Louisa; Gui, Xianyong et al.

Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4; a mini review.

Mardi, Amirhossein; Aghebati-Maleki, Leili

Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review.

Wei, Chaoyong; Tang, Changli; Zhang, Yao et al.

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic re

Gu, Lihu; Khadaroo, Parikshit Asutosh; Su, Hui et al.

Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibi

Lin, Anqi; Huang, Lihaoyun; Jiang, Aimin et al.

Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.

Kovács, Szonja Anna; Győrffy, Balázs

Targeting TNFR2 for cancer immunotherapy: recent advances and future directions.

Li, Linxue; Ye, Ruiwei; Li, Yingying et al.

Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy.

Jafari, Zahra; Raoufi, Atieh; Athari, Seyyed Shamsadin et al.

The use of immunotherapy in the treatment of melanoma.

Achkar, Tala; Tarhini, Ahmad A

Targeting immune checkpoints in hematological malignancies.

Salik, Basit; Smyth, Mark J; Nakamura, Kyohei

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.

Zhang, Hao; Dai, Ziyu; Wu, Wantao et al.

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.

Wu, Kongju; Yi, Ming; Qin, Shuang et al.

Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through

Davis, Ruth J; Ferris, Robert L; Schmitt, Nicole C

An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.

Mahadevia, Himil; Uson Junior, Pedro Luiz Serrano; Wang, Jing et al.

Immune checkpoint inhibition for the treatment of mesothelioma.

Nowak, Anna K; McDonnell, Alison; Cook, Alistair

Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results.

Stella, Leonardo; Hollande, Clemence; Merabet, Yasmina Ben et al.

Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the

Chen, Mengting; He, Zhichao; Zhu, Jianhong et al.

Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review.

Vyas, Charmy; Moshyk, Andriy; Fusaro, Gina et al.

[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology

Gaultier De Saint Basile, Hortense; Poisson, Caroline; Arrondeau, Jennifer et al

Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.

Pasquali, Sandro; Chiarion-Sileni, Vanna; Rossi, Carlo Riccardo et al.

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review.

Mearns, Elizabeth S; Bell, Jill A; Galaznik, Aaron et al.

Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer.

Longoria, Teresa C; Eskander, Ramez N

Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.

Nakane, Tomoyuki; Mitsuyama, Keiichi; Yamauchi, Ryosuke et al.

Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review.

Ornstein, Moshe C; Garcia, Jorge A

Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Ce

Anderson, Ronald; Theron, Annette J; Rapoport, Bernardo L

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.

Khair, Duaa O; Bax, Heather J; Mele, Silvia et al.

Exploiting Human NK Cells in Tumor Therapy.

Vacca, Paola; Pietra, Gabriella; Tumino, Nicola et al.

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.

Liu, Maobai; Cheng, Xitong; Ni, Ruping et al.

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer imm

Kurago, Zoya; Guo, Gang; Shi, Huidong et al.

The current status and future of targeted-immune combination for hepatocellular carcinoma.

Hao, Liyuan; Li, Shenghao; Ye, Fanghang et al.

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-anal

Noori, Maryam; Azizi, Shadi; Mahjoubfar, Aref et al.

Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.

Zhang, M Lisa; Neyaz, Azfar; Patil, Deepa et al.

Enterocolitis due to immune checkpoint inhibitors: a systematic review.

Soularue, Emilie; Lepage, Patricia; Colombel, Jean Frederic et al.

Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of

Mobini, Narciss; Dhillon, Rummit; Dickey, Jason et al.

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical oppor

Yin, Nanhao; Li, Xintong; Zhang, Xuanwei et al.

Immune Checkpoints and Their Inhibition in T-Cell Lymphomas.

Seňavová, Jana; Rajmonová, Anežka; Heřman, Václav et al.

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental

Palicelli, Andrea; Croci, Stefania; Bisagni, Alessandra et al.

Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.

Haibe, Yolla; El Husseini, Ziad; El Sayed, Rola et al.

Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Tre

Qiu, Junyu; Cheng, Zilin; Jiang, Zheng et al.

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review.

Profili, Nicia I; Castelli, Roberto; Gidaro, Antonio et al.

Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.

Usta, Sena Zeynep; Uchihashi, Toshihiro; Kodama, Shingo et al.

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Rev

Grassadonia, Antonino; Sperduti, Isabella; Vici, Patrizia et al.

The Role of CTLA-4 in T Cell Exhaustion in Chronic Hepatitis B Virus Infection.

Apol, Ása Didriksen; Winckelmann, Anni Assing; Duus, Rasmus Bülow et al.

Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.

Menotti, Sara; Giampietro, Antonella; Raia, Salvatore et al.

Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review.

Angelousi, Anna; Papalexis, Petros; Karampela, Athina et al.

Immune checkpoint inhibitors in metastatic melanoma therapy (Review).

Shah, Vedant; Panchal, Viraj; Shah, Abhi et al.

First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network me

Mutlu, Hasan; Bozcuk, Hakan; Artaç, Mehmet et al.

Immune checkpoint inhibitors in cancer therapy.

Webb, Eika S; Liu, Peng; Baleeiro, Renato et al.

Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.

Oliveira, Marcos C B; de Brito, Marcelo H; Simabukuro, Mateus M

PD-1/PD-L Axis in Neuroinflammation: New Insights.

Manenti, Susanna; Orrico, Mario; Masciocchi, Stefano et al.

Immune Checkpoint Blockade - How Does It Work in Brain Metastases?

Lorger, Mihaela; Andreou, Tereza; Fife, Christopher et al.

Immune Checkpoints and Innovative Therapies in Glioblastoma.

Romani, Massimo; Pistillo, Maria Pia; Carosio, Roberta et al.

Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Ana

Liu, Kang; Qin, Zhongke; Xu, Xueqiang et al.

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.

Park, Robin; Lopes, Laercio; Cristancho, Cagney R et al.

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.

Kong, Benjamin Y; Bolton, Holly; Kim, Julius W et al.

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.

Russell, Bonnie L; Sooklal, Selisha A; Malindisa, Sibusiso T et al.

Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review.

Luo, Yingzhe; Cai, Xuebin; Yang, Biao et al.

Relationship between single-nucleotide polymorphisms and cancer immunotherapy efficacy and toxicity: a systematic review

Specchia, Monia; Siringo, Marco; Mazzotti, Eva et al.

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis.

Gemelli, Maria; Cortinovis, Diego Luigi; Baggi, Alice et al.

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.

Mytareli, Chrysoula; Ziogas, Dimitrios C; Karampela, Athina et al.

Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Bes

Roque, Katia; Ruiz, Rossana; Mas, Luis et al.

Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune

Trichkova, Kremena Petrova; Görtler, Franziska; Bjørge, Line et al.

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Chen, Chieh-Hsun; Yu, Hsin-Su; Yu, Sebastian

Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients.

Pichon, Samuel; Aigrain, Pauline; Lacombe, Charlotte et al.

Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and m

Wen, Wen; Zhang, Yong; Zhang, Hua et al.

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.

Schmidt, Emmett V

Medication-associated thyroid eye disease: a review.

Ang, Terence; Almater, Abdullah; Selva, Dinesh

The current status of checkpoint inhibitors in metastatic bladder cancer.

Fahmy, Omar; Khairul-Asri, Mohd Ghani; Stenzl, Arnulf et al.

Novel Immunotherapy Combinations.

Bashir, Babar; Wilson, Melissa A

Liver graft rejection following immune checkpoint inhibitors treatment: a review.

Hu, Bo; Yang, Xiao-Bo; Sang, Xin-Ting

Immune Checkpoint Inhibitors in Malignant Melanoma: Anti-PD-1, Anti-CTLA-4 and Anti-LAG-3 Therapies.

Allen-Tejerina, Andrea M; Giannakis, Periklis; Ho Lai Yau, Thomas et al.

Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.

Ryba-Stanisławowska, Monika

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.

Wang, Jinyu; Li, Zehua; Yin, Hongbo

First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.

Ackermann, Christoph Jakob; Adderley, Helen; Ortega-Franco, Ana et al.

Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Met

Landre, Thierry; Des Guetz, Gaetan; Chouahnia, Kader et al.